Chd5 requires PHD-mediated histone 3 binding for tumor suppression.

Area of Science:

• Molecular Biology
• Cancer Biology
• Epigenetics

Background:

• Chromodomain Helicase DNA binding protein 5 (CHD5) is a tumor suppressor located at the 1p36 genomic region, frequently deleted in cancers.
• The role of CHD5 in tumor suppression and its interaction with chromatin remain largely uncharacterized.

Purpose of the Study:

• To investigate the mechanism by which CHD5 exerts its tumor-suppressive function.
• To determine if CHD5's interaction with chromatin is essential for its role in cancer.

Main Methods:

• Chromatin immunoprecipitation (ChIP) studies to map CHD5 binding sites genome-wide.
• Analysis of CHD5 mutations affecting histone H3 binding.
• In vivo studies using neuroblastoma models to assess tumor suppression and differentiation induction.

Main Results:

• CHD5 directly binds the unmodified N terminus of histone H3 via its tandem plant homeodomains (PHDs).
• CHD5 preferentially binds to genomic loci lacking the active H3K4me3 mark and targets genes implicated in cancer.
• Mutations disrupting H3 binding abolish CHD5's ability to inhibit proliferation, modulate transcription, induce differentiation, and suppress tumor growth in vivo.

Conclusions:

• CHD5 functions as a tumor suppressor by binding to unmodified histone H3.
• This interaction is critical for orchestrating chromatin-mediated transcriptional programs essential for preventing tumorigenesis.
• CHD5's ability to bind H3 is indispensable for its tumor-suppressive activities, including differentiation induction and cancer growth inhibition.